ORLENI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 213
AS - Asia 91
EU - Europa 60
Totale 364
Nazione #
US - Stati Uniti d'America 211
SG - Singapore 50
CN - Cina 36
IT - Italia 22
FI - Finlandia 7
FR - Francia 7
DE - Germania 6
IE - Irlanda 5
RU - Federazione Russa 4
LT - Lituania 3
VN - Vietnam 3
CA - Canada 2
GB - Regno Unito 2
IN - India 2
RS - Serbia 2
BE - Belgio 1
PL - Polonia 1
Totale 364
Città #
Singapore 46
Santa Clara 25
Chandler 23
Boardman 19
Fairfield 16
Cambridge 14
Ashburn 11
Beijing 11
San Diego 9
Houston 7
Seattle 7
New York 6
Trieste 6
Ann Arbor 5
Helsinki 5
Medford 4
Princeton 4
Woodbridge 4
Des Moines 3
Wilmington 3
Belluno 2
Fort Worth 2
Frankfurt am Main 2
Sacile 2
San Giorgio A Cremano 2
Toronto 2
Brussels 1
Chiampo 1
Dalian 1
Dublin 1
Gdansk 1
Guangzhou 1
Hangzhou 1
Hanoi 1
Hyderabad 1
Jinan 1
Lanzhou 1
Lappeenranta 1
London 1
Montegrotto Terme 1
Munich 1
Naples 1
Ocala 1
Prescot 1
Redmond 1
Taizhou 1
Zhoukou 1
Totale 261
Nome #
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 63
A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma 55
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 46
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring 42
A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring 22
Pharmacology and pharmacokinetics of tazemetostat 19
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 16
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 16
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 15
Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring 12
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 11
A fast and validated LC-MS/MS method to quantify lenvatinib in dried blood spot 11
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 10
Quantitation of tazemetostat in human plasma using liquid chromatography–tandem mass spectrometry 10
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 10
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 8
Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series 7
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions 7
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 5
Totale 385
Categoria #
all - tutte 2.421
article - articoli 2.421
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.842


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017 0 0 0 0 0 0 0 2 0 4 1 10
2020/202136 0 10 0 5 0 0 0 8 4 9 0 0
2021/202244 0 0 2 0 2 16 0 3 3 6 2 10
2022/202354 7 5 3 4 10 5 0 2 11 2 3 2
2023/202436 0 5 0 1 4 10 4 4 3 0 5 0
2024/2025198 1 66 26 23 47 35 0 0 0 0 0 0
Totale 385